| LP435845-5 | ACTH heterophile Ab interference | COMPONENT | 1 |
| LP435846-3 | Adaptor Protein 3 Beta2 Ab.IgG | COMPONENT | 1 |
| LP435850-5 | Eculizumab Monitoring Panel | COMPONENT | 1 |
| LP435851-3 | Ravulizumab Monitoring Panel | COMPONENT | 1 |
| LP435852-1 | Calbindin D28K | COMPONENT | 1 |
| LP435854-7 | SARS-CoV-2 | COMPONENT | |
| LP435865-3 | Cortisol, glucose and somatotropin post glucagon stimulation panel | COMPONENT | 1 |
| LP435866-1 | Glucose and somatotropin post glucagon stimulation panel | COMPONENT | 1 |
| LP435867-9 | Cortisol post arginine stimulation panel | COMPONENT | 1 |
| LP435874-5 | B-cell acute lymphocytic leukemia | COMPONENT | 1 |
| LP435876-0 | Lung cancer panel | COMPONENT | 1 |
| LP435882-8 | Candida albicans glabrata, tropicalis parapsilosis DNA | COMPONENT | |
| LP435883-6 | Candida albicans+glabrata+tropicalis+parapsilosis DNA | COMPONENT | 1 |
| LP435884-4 | Candida albicans+glabrata+tropicalis+parapsilosis | COMPONENT | |
| LP435885-1 | Mycoplasma genitalium and Mycoplasma hominis | COMPONENT | |
| LP435886-9 | Candida dubliniensis+lusitaniae+krusei+auris DNA | COMPONENT | |
| LP435890-1 | Candida dubliniensis+lusitaniae+krusei+auris DNA | COMPONENT | 1 |
| LP435892-7 | Candida dubliniensis+lusitaniae+krusei+auris | COMPONENT | |
| LP435893-5 | Breathing patterns | COMPONENT | 1 |
| LP435894-3 | Arm | COMPONENT | |
| LP435895-0 | Legs | COMPONENT | 1 |
| LP435896-8 | Neonatal infant pain scale panel (NIPS) | COMPONENT | 1 |
| LP435898-4 | Total score (0 to 7) | COMPONENT | 1 |
| LP435914-9 | 1-Deoxysphingosine | COMPONENT | 1 |
| LP435915-6 | 1-deoxymethylsphinganine | COMPONENT | 1 |
| LP435916-4 | 1-deoxymethylsphingosine | COMPONENT | 1 |
| LP435926-3 | Vitamin B3 and metabolites panel | COMPONENT | 1 |
| LP435941-2 | Glucose, somatotropin and cortisol post insulin administration | COMPONENT | 1 |
| LP435942-0 | B-Cell lymphoblastic leukemia monitoring minimal residual disease detection | COMPONENT | 3 |
| LP435943-8 | Clot initiation, kaolin induced | COMPONENT | |
| LP435944-6 | addition of heparinase | CHALLENGE | |
| LP435954-5 | 3-hydroxypropyl mercapturate | COMPONENT | |
| LP435977-6 | Glucose | COMPONENT | 1 |
| LP435979-2 | Glucose^1.5H post dose glucagon | COMPONENT | |
| LP435980-0 | 60M post dose glucagon | CHALLENGE | |
| LP435981-8 | Fasting post dose insulin IV | CHALLENGE | |
| LP435982-6 | Fasting post dose insulin IV | COMPONENT | |
| LP435991-7 | Fasting post dose insulin IV | CHALLENGE | |
| LP435997-4 | Cell-free DNA.donor/Cell-free DNA.total^post transplant | COMPONENT | 1 |
| LP435998-2 | Glucose^1H post dose glucagon | COMPONENT | 1 |
| LP435999-0 | Steroid drug screening panel | COMPONENT | 1 |
| LP436001-4 | Glucose^2H post dose glucagon | COMPONENT | 1 |
| LP436002-2 | Glucose^2.5H post dose glucagon | COMPONENT | 1 |
| LP436004-8 | Glucose^3H post dose glucagon | COMPONENT | 1 |
| LP436006-3 | Cortisol^30M post dose glucagon | COMPONENT | 1 |
| LP436007-1 | Cortisol^60M post dose glucagon | COMPONENT | 1 |
| LP436008-9 | Cortisol^2.5H post dose glucagon | COMPONENT | 1 |
| LP436009-7 | Cortisol^3H post dose glucagon | COMPONENT | 1 |
| LP436021-2 | Ki-67 Nuclear Ag & p16INK4a Ag | COMPONENT | 2 |
| LP436024-6 | Maraviroc anticipated activity | COMPONENT | 1 |